Registry for long-term follow-up of CML patients who discontinued **Imatinib after Complete Cytogenetic Response**

1st Form (Baseline) (time of diagnosis)

Demographics/Patient Characteristics		
Center	Demographics/ration characteristics	
Patient ID		
Date of birth	ddmmyy	
Gender	0=male 1=female	
Currently smoker	0=no 1=yes	
"Pack-years"	Number of daily smoked cigarettes x years / 20	<u></u>
Living together with a partner	0=no 1=yes	LI
Marital status	1=married 2=never been married 3=divorced 4=widowed	
Highest graduation basic	1=secondary school 2=intermediate school 3=high school graduation, A-levels 4=university	LI
Employment status	1=unemployed 2=full-time employed 3=part-time employed 4=not applicable	LI
Weight	kg	<u> </u>
Height	cm	_ _
Disease	characteristics (to be recorded prior to any tro	eatment)
Date of diagnosis	ddmmyy	
WHO Performance Scale	%	
Karnofsky-Index	%	
Disease related symptoms	0=no 1=yes	LI
Extramedullary manifestations (apart from liver and spleen)	0=no 1=yes	LI
	If yes, please specify	
	cm below costal margin, palpated	
Spleen size	The longest diameter in ultrasound, cm	
Liver size	cm in MCL	
Hematology		
Hemoglobin	g/dl	
Hematokrit	%	
WBC	x 10 ⁹ /l	
Platelets	x 10 ⁹ /l	
Differential (PB)		
Blasts (a minim	num of 200 cells should be counted under the mid	croscope)
Promyelocytes	9%	
Myelocytes	%	
Metamyelocytes	9%	
Bands		
Dalius	%	

	Patient ID	
Date of birth (ddmi	nyy) _ _	
Gender (0=male 1:		

Polymorphic nucleated cells	%	
Basophils	%	
Eosinophils	%	
Monocytes	%	
Lymphocytes	%	
Normoblasts	(pro 100 leukocytes)	
	Differential (BM)	'
BM cellularity	1=low	
(histopathology or smear)	2=normal 3=high	
Blasts in BM	% na=no aspiration nd=not done	
Promyelocytes in BM	% na=no aspiration nd=not done	
Basophils in BM	% na=no aspiration nd=not done	
Eosinophils in BM	% na=no aspiration nd=not done	
	Cytogenetic features	
Ph-chromosome status	1=positive 2=negative 3=unknown	Ш
Number of evaluated metaphases		
Number of Ph-positive metaphases		
Karyotype		
Other clonal chromosomal anomalities in Ph- positive cells, if yes, please specify % and	0=no 1=yes	
type	%	
	type	
Other clonal chromosomal anomalities in Phnegative cells, if yes, please specify % and	0=no 1=yes	
type	%	
	type	
Molecular biology		
Date of molecular analysis	ddmmyy	
Source of material	1=PB 2=BM	
Volume	ml	_ _
Ratio BCR-ABL/ABL	%	<u> </u>
Other control gene	Please specify	
Ratio BCR-ABL/other gene	%	
Nested PCR	1=positive 2=negative 4=not done	Ш
Level of BCR-ABL transcript, i.e. quantitative		

nstitution:	Date (ddmmyy):	Signature:

Center _	Patient ID _
Date of birth (ddmmy	y) _ _
Gender (0=male, 1=fe	emale)

	1=b2a2	
	2=b3a2	
	3=b2a3	
	4=b3a3	
Transcript	5=e1a2	
	6=b2a2 and b3a2	
	7=e6a2	
	8=e19a2	
	9=others	
	If others, please specify	
ABL-BCR transcript	1=positive	
	2=negative	
	3=unknown	
Deletion of genetic material on chromosome	0=no	
9q+ (FISH)	1=yes	
	1=A	
	2=B	
HLA-Status	3=C	
	4=DR	
	5=DQ	
	Treatment	
	Pre-treatment: 0=no	
	1=yes If yes, please specify below:	
	if yes, picase specify below.	
	Drug: Dosis:	
	Period of administration	
	(ddmmyy): from	to
Pre-treatment	Drug:	
	Dosis:	
	Period of administration (ddmmyy): from	to
	Drug: Dosis:	
	Period of administration	
	(ddmmyy): from	to
Start of Imatinib treatment	ddmmyy	
Dosage per day		
End of Imatinib treatment	ddmmyy	
	please specify the cause	
<u> </u>		·

Institution:	Date (ddmmyy):	Signature:

Center Patient ID Date of birth (ddmmyy)	
Gender (0=male, 1=female)	
	New CML treatment: 0=no
	I=yes
	Drug: Dosis: Period of administration
	Dosis: Period of administration
	(ddmmyy): from to
	Drug: Dosis:
	Period of administration: from to
	Drug:
New CML treatment (after discontinuation of Imatinib treatment)	Dosis: Period of administration: from to
	Drug:
	Drug: Dosis: Period of administration: from _ _ _ to _ _ _
	Drug:
	Dosis: Period of administration: from to
	Drug:

Period of administration: from _____ to ____ to _____

Institution: _____ Date (ddmmyy): |__| | | | | Signature: ____